Revenio: Holistic value creation on the horizon
Inderes
Under the iCare brand, Revenio offers world-class tonometers, fundus imaging devices and perimeters. In recent years, the company has added software solutions to its offering, moving from being an equipment provider to a holistic eye diagnostics solution provider. The core business is growing very profitably, the market has sound growth drivers, and the company’s products have strong competitive advantages. At the same time, the company is creating future growth by developing new growth initiatives, of which Revenio has an excellent track record.
Login required
This content is only available for logged in users
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Read more on company pageKey Estimate Figures18.03.2023
| 2022 | 23e | 24e | |
|---|---|---|---|
| Revenue | 97.0 | 111.4 | 129.6 |
| growth-% | 23.1 % | 14.9 % | 16.3 % |
| EBIT (adj.) | 30.9 | 34.0 | 39.5 |
| EBIT-% (adj.) | 31.8 % | 30.5 % | 30.5 % |
| EPS (adj.) | 0.86 | 0.98 | 1.15 |
| Dividend | 0.36 | 0.42 | 0.55 |
| Dividend % | 0.9 % | 3.5 % | 4.5 % |
| P/E (adj.) | 44.6 | 12.4 | 10.6 |
| EV/EBITDA | 30.6 | 8.2 | 6.6 |
Forum discussions
